- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04102852
Lactobacillus Rhamnosus GG (ATCC 53103) in Mild-moderately Active UC Patients (LGGinUC)
The Role of Lactobacillus Rhamnosus GG (ATCC 53103) in the Modulation of the Inflammatory Process in the Mucosa of Ulcerative Colitis (UC) Patients With Mild-moderate Clinical Activity
Study Overview
Status
Intervention / Treatment
Detailed Description
Probiotic bacteria have been proposed as therapeutic option in several pathologic conditions, but their utilization is often not evidence-based driven. In inflammatory bowel disease (IBD), consistent heterogenity exists among published clinical studies. Aim of the present clinical study is to evaluate the effect of Lactobacillus rhamnosus GG (LGG), the probiotic bacteria most extensively investigated, with solid safety data and proven anti-inflammatory effect in experimental models, in ulcerative colitis (UC) patients, with a rigorous methodology, a well defined protocol, and with relevant outcomes clearly set.
This study is a randomized double-blind clinical trial that intends to evaluate the efficacy and safety of LGG administration at two different doses, for 1 month, in UC patients with mild-moderate disease activity in therapy with oral mesalamine.The eligible patients will be identified by a screening visit (T-1), with consideration of inclusion and exclusion criteria, and informed consent will be signed. Then the patients will have a 4 weeks wash-out period, when oral mesalamine will be suspended, and biochemical tests [total blood count, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and serum protein electrophoresis], and endoscopic examination with biopsies will be performed. The patients will be then evaluated again prior to the randomization to regular or double dose group (T0), and clinical activity and quality of life will be assessed. Patients will be randomized to assume a regular (LGG 1.2 × 10^10 CFU/day, 2 capsules a day) or a double (LGG 2.4 × 10^10 CFU/day, 4 capsules a day) dose of LGG for 1 month. After 4 weeks of treatment, patients will be re-evaluated (T1), with physical examination and interview, and rectum-sigmoidoscopy with biopsies will be performed. The patients will then be allowed to assume the therapy they were taking at T-1 visit (mesalamine), and will be assessed for the last time after 4 weeks after treatment completition (T2), with physical examination and interview. Efficacy of therapy will be evaluated by comparison of clinical, endoscopic, histological, biochemical and molecular data, pre- and post-treatment (T1 vs. T0). Randomization of patients in the groups will be performed by a computer-generated randomization list, in a double blind fashion. Clinical activity will be evaluated by Clinical Mayo Score calculation. Quality of life will be evaluated by specific validated tests. Endoscopic activity will be evaluated by Endoscopic Mayo Score calculation, by an endoscopist blinded to clinical data of patients. Histologic activity will be evaluated by expert anatomopathologists, by means of Geboes score. Molecular activity of LGG will be evaluated by assessment of bacteria adhesion to the colonic mucosa, measured by real-time(RT)-Polymerase Chain Reaction (PCR) with specific primers on total DNA extracted by bioptic samples (as already described), and by quantification of expression of pro- and anti-inflammatory cytokines, before and after probiotic treatment, by means of RT-PCR on total RNA extracted from bioptic samples (as already described).
Safety of LGG treatment will be assessed by weekly phone calls to the patients, in order to investigate the unexpected occurence of side-effects, and with direct physical examination and biochemical tests at the end of the study period (T1). Possible LGG translocation will be evaluated by RT-PCR with specific primers on total DNA extracted from peripheral blood collected from patients at the end of treatment (T1).
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Roma, Italy, 00184
- S. Giovanni Addolorata Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- firm diagnosis of UC (clinical, endoscopic and histological criteria) from at least 1 year
- mild-moderate clinical activity (Clinical Mayo score 2-4)
- patient taking oral mesalamine
- Informed consent obtained and signed at the screening visit (T-1)
Exclusion Criteria:
- Pregnant women
- Serious co-morbidities (i.e. autoimmune pathologies, cancer, chronic infectious conditions, immunocompromised patients)
- Patients at first diagnosis of UC
- Patients with current immunosuppressive and/or biologic therapy for IBD, or who had immunosuppressive and/or biologic therapy for IBD in the last year
- Patients with current oral and/or topical steroid therapy, or who had oral steroid therapy for disease flare in the last 6 months
- Patients with current topical UC therapy (suppositories, enemas, foams)
- Patients with current antibiotic/probiotic therapy, or who had antibiotic/probiotic therapy in the last 3 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LGG regular dose
Patients taking LGG 1.2 × 10^10 CFU/day, 2 capsules a day, for 1 month
|
probiotic administration at two different doses for 1 month
|
Experimental: LGG double dose
Patients taking LGG 2.4 × 10^10 CFU/day, 4 capsules a day, for 1 month
|
probiotic administration at two different doses for 1 month
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline Clinical Mayo Score after treatment [Efficacy]
Time Frame: 1 month
|
Improvement of clinical inflammatory activity (Clinical Response) evaluated by reduction of Clinical Mayo Score at the end of the treatment comparing to pre-treatment value
|
1 month
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: every week, through 1 month
|
Recording and description of any side effect possibly related to probiotic administration
|
every week, through 1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mucosal Adhesion of LGG to Colonic Mucosa
Time Frame: 1 month
|
Effective LGG colonization in colonic mucosa as measured by real-time PCR detection of LGG in bioptic samples of colon of LGG treated patients at the end of the treatment
|
1 month
|
Quality of Life Improvement
Time Frame: 1 month
|
Improvement of QoL parameters as measured and assessed by Short Form-36 Health Survey (SF-36), before and after probiotic treatment.
The SF-36 is a 36-item patient-reported questionnaire that covers eight health domains: physical functioning (10 items), bodily pain (2 items), role limitations due to physical health problems (4 items), role limitations due to personal or emotional problems (4 items), emotional well-being (5 items), social functioning (2 items), energy/fatigue (4 items), and general health perceptions (5 items).
Scores for each domain range from 0 to 100, with a higher score defining a more favorable health state.
The final score is generated by a formula that combines the different domains' score, and expressed by a score with a 0 to 100 range,with a higher score defining a more favorable health state
|
1 month
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Cristiano Pagnini, MD, PhD, S.Giovanni Addolorata Hospital
- Study Director: Gianfranco Delle Fave, MD, Onlus S. Andrea
Publications and helpful links
General Publications
- Pagnini C, Corleto VD, Martorelli M, Lanini C, D'Ambra G, Di Giulio E, Delle Fave G. Mucosal adhesion and anti-inflammatory effects of Lactobacillus rhamnosus GG in the human colonic mucosa: A proof-of-concept study. World J Gastroenterol. 2018 Nov 7;24(41):4652-4662. doi: 10.3748/wjg.v24.i41.4652.
- Pagnini C, Martorelli M, Lanini C, Delle Fave G. Development of an Ex Vivo Organ Culture Technique to Evaluate Probiotic Utilization in IBD. J Clin Gastroenterol. 2016 Nov/Dec;50 Suppl 2, Proceedings from the 8th Probiotics, Prebiotics & New Foods for Microbiota and Human Health meeting held in Rome, Italy on September 13-15, 2015:S179-S182. doi: 10.1097/MCG.0000000000000698.
- Derwa Y, Gracie DJ, Hamlin PJ, Ford AC. Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. Aliment Pharmacol Ther. 2017 Aug;46(4):389-400. doi: 10.1111/apt.14203. Epub 2017 Jun 27.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LGG/UC/001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ulcerative Colitis Chronic Moderate
-
Rise Therapeutics LLCUniversity of Colorado, Denver; Mayo ClinicRecruitingUlcerative Colitis | Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic | Ulcerative Colitis Chronic MildUnited States
-
Protagonist Therapeutics, Inc.CompletedUlcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic SevereUnited States, Austria, Bulgaria, Canada, Georgia, Germany, Hungary, Italy, Korea, Republic of, Poland, Russian Federation, Serbia, Ukraine
-
Wolfson Medical CenterNot yet recruitingUlcerative Colitis | Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic MildIsrael, Switzerland, Italy, Netherlands
-
IRCCS San RaffaeleRecruitingUlcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic SevereItaly
-
Oncostellae S.LCompletedUlcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic SevereSpain, Ukraine
-
Assembly BiosciencesTerminatedUlcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic MildUnited States, Canada
-
Dayanand Medical College and HospitalColitis & Crohn's Foundation (India)UnknownUlcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic MildIndia
-
Xijing Hospital of Digestive DiseasesNot yet recruitingUlcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic Severe | Rectal UlcerChina
-
The Second Hospital of Nanjing Medical UniversityUnknownUlcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic MildChina
-
Mohammed Bin Rashid University of Medicine and...Dubai Health Authority; Mediclinic Middle East; Rashid HospitalRecruitingUlcerative Colitis Chronic Moderate | Crohn Colitis | Ulcerative Colitis Chronic MildUnited Arab Emirates
Clinical Trials on Lactobacillus rhamnosus GG ATCC 53103
-
Istanbul UniversityCompletedDiabetes Mellitus, Type 2
-
Massachusetts General HospitalCompletedHealthy | ElderlyUnited States
-
Massachusetts General HospitalCompletedHealthy | ElderlyUnited States
-
Medical University of WarsawAdamed Pharma S.A.Not yet recruitingAntibiotic-associated DiarrheaPoland
-
Johann Wolfgang Goethe University HospitalCompleted
-
VA Eastern Colorado Health Care SystemUniversity of Colorado, Denver; University of Colorado, BoulderRecruiting
-
Massachusetts General HospitalCompleted
-
Medical University of LodzCompletedHealthy | Anxiety | Stress-related Problem
-
Washington University School of MedicineNorthwestern University; Wayne State University; Columbia University; Brown University and other collaboratorsCompletedGastroenteritisUnited States
-
Patricia L. HibberdCompletedHealthy | InfluenzaUnited States